Nuveen
CATX icon

Nuveen’s Perspective Therapeutics CATX Stock Holding History

Nuveen’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Sell
336,817
-573,404
-63% -$2.17M ﹤0.01% 2872
2026
Q1 		$3.8M Sell
910,221
-363,786
-29% -$1.54M ﹤0.01% 1996
2025
Q4 		$3.5M Sell
1,274,007
-34,635
-3% -$98.8K ﹤0.01% 2065
2025
Q3 		$4.49M Sell
1,308,642
-988,672
-43% -$3.6M ﹤0.01% 1954
2025
Q2 		$7.9M Buy
2,297,314
+1,054,772
+85% +$2.78M ﹤0.01% 1649
2025
Q1 		$2.65M Buy
1,242,542
+520,494
+72% +$1.56M ﹤0.01% 2219
2024
Q4 		$2.3M Sell
722,048
-108,165
-13% -$883K ﹤0.01% 2327
2024
Q3 		$11.1M Buy
830,213
+569,286
+218% +$7.57M ﹤0.01% 1539
2024
Q2 		$2.6M Buy
+260,927
New +$3.77M ﹤0.01% 2255

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Nuveen's CATX Position: Q2 2026 in Review

Nuveen reduced its Perspective Therapeutics (CATX) stake by 63% in Q2 2026, selling an estimated $2.17M and leaving 336,817 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

Nuveen first reported a position in CATX in Q2 2024 and has held it in 9 quarters since. The position peaked at $11.1M in Q3 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Nuveen held 336,817 shares of Perspective Therapeutics worth $1.15M as of Q2 2026.
  • Nuveen sold 573,404 Perspective Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Perspective Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2872 holding.
  • Nuveen first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Nuveen's Perspective Therapeutics position peaked at $11.1M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.